Upadacitinib Led to Sustained, 140-Week Improvements for Atopic Dermatitis Patients

These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.

Related Keywords

United States ,Chicago ,Illinois ,American ,Linkedin Vimalh Prajapati ,Vimalh Prajapati , ,University Of Calgary ,American Academy Of Dermatology ,Drug Administration ,Atopic Dermatitis ,Annual Meeting ,Eczema Area ,Severity Index ,Dermatology Life Quality Index ,Worst Pruritus Numerical Rating Scale ,Total Symptom Score ,Skin Pain ,Patient Oriented Eczema Measure ,Daily Activities ,Emotional State ,